ES2494015T3 - Composiciones para tratar nauseas y vómitos de origen central - Google Patents
Composiciones para tratar nauseas y vómitos de origen central Download PDFInfo
- Publication number
- ES2494015T3 ES2494015T3 ES10805301.8T ES10805301T ES2494015T3 ES 2494015 T3 ES2494015 T3 ES 2494015T3 ES 10805301 T ES10805301 T ES 10805301T ES 2494015 T3 ES2494015 T3 ES 2494015T3
- Authority
- ES
- Spain
- Prior art keywords
- vomiting
- administered
- nausea
- patient
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Paints Or Removers (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26247009P | 2009-11-18 | 2009-11-18 | |
| US262470P | 2009-11-18 | ||
| US38270910P | 2010-09-14 | 2010-09-14 | |
| US382709P | 2010-09-14 | ||
| PCT/IB2010/003106 WO2011061622A1 (en) | 2009-11-18 | 2010-11-18 | Compositions for treating centrally mediated nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2494015T3 true ES2494015T3 (es) | 2014-09-12 |
Family
ID=43608757
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10805301.8T Active ES2494015T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar nauseas y vómitos de origen central |
| ES14151676.5T Active ES2559475T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos de origen central |
| ES14151683.1T Active ES2595077T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
| ES14151678.1T Active ES2623503T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14151676.5T Active ES2559475T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos de origen central |
| ES14151683.1T Active ES2595077T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
| ES14151678.1T Active ES2623503T3 (es) | 2009-11-18 | 2010-11-18 | Composiciones para tratar náuseas y vómitos mediados centralmente |
Country Status (40)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| PT2722045T (pt) | 2009-11-18 | 2016-10-18 | Helsinn Healthcare Sa | Composições para o tratamento de náuseas e vómitos mediadas centralmente |
| WO2013004766A1 (en) * | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
| ES2579616T3 (es) * | 2011-10-18 | 2016-08-12 | Helsinn Healthcare Sa | Combinaciones terapéuticas de netupitant y palonosetrón |
| US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| CN103520725B (zh) * | 2012-07-05 | 2017-10-24 | 海思科医药集团股份有限公司 | 一种治疗呕吐的药物组合物 |
| CA2978736C (en) | 2015-03-04 | 2023-11-07 | Vanda Pharmaceuticals Inc. | Dosing regimen of tradipitant |
| CN106902086B (zh) * | 2015-12-23 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种包含奈妥匹坦的固体组合物 |
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| CN108853010A (zh) * | 2017-05-15 | 2018-11-23 | 和龙 | 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途 |
| CN109200018A (zh) * | 2017-07-04 | 2019-01-15 | 南京诺瑞特医药科技有限公司 | 含有奈妥吡坦的微乳制剂 |
| KR20250140655A (ko) * | 2017-11-17 | 2025-09-25 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 위장 질환의 치료 방법 |
| MX2020008137A (es) * | 2018-02-02 | 2020-10-19 | Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro | Formulaciones orales y usos de las mismas. |
| AU2021407138A1 (en) * | 2020-12-25 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist |
| EP4385500A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Fixed dose combination comprising netupitant and palonosetron |
| EP4633608A1 (en) | 2022-12-12 | 2025-10-22 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
| KR20250125376A (ko) | 2022-12-12 | 2025-08-21 | 알프레드 이. 티펜바흐어 게엠베하 운트 ＆ 코. 카게 | 네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제 |
| EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
| WO2025246530A1 (en) * | 2024-05-30 | 2025-12-04 | The Chinese University Of Hong Kong | Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL166272B1 (pl) | 1989-11-28 | 1995-04-28 | Syntex Inc | Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| US6297395B1 (en) | 1995-11-10 | 2001-10-02 | The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Calixarenes and their use for sequestration of metals |
| EP1394150B1 (en) | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| PT1303490E (pt) | 2000-07-14 | 2008-09-04 | Hoffmann La Roche | Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina |
| MXPA03005169A (es) | 2000-12-14 | 2003-09-22 | Hoffmann La Roche | Matriz lipidica auto-emulsificante. |
| DE10393729T5 (de) | 2002-11-15 | 2005-10-13 | Helsinn Healthcare S.A. | Verfahren zur Behandlung von Emesis |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
| TWI355936B (en) * | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
| MXPA05010819A (es) * | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| US7479312B2 (en) | 2005-07-07 | 2009-01-20 | Konica Minolta Opto, Inc. | Retardation film, polarizing plate, and liquid crystal display device |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| ES2402581T3 (es) | 2006-02-23 | 2013-05-06 | Pfizer Limited | Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4 |
| CN101573106B (zh) * | 2006-10-24 | 2013-07-24 | 赫尔辛医疗股份公司 | 具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂 |
| US20110014117A1 (en) * | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| MX2010006854A (es) * | 2007-12-18 | 2010-09-09 | Schering Corp | Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. |
| PT2722045T (pt) | 2009-11-18 | 2016-10-18 | Helsinn Healthcare Sa | Composições para o tratamento de náuseas e vómitos mediadas centralmente |
-
2010
- 2010-11-18 PT PT141516831T patent/PT2722045T/pt unknown
- 2010-11-18 GE GEAP201012752A patent/GEP20156226B/en unknown
- 2010-11-18 RS RSP20140423 patent/RS53491B1/sr unknown
- 2010-11-18 KR KR1020127015676A patent/KR101615108B1/ko active Active
- 2010-11-18 CN CN2010800521070A patent/CN102655864A/zh active Pending
- 2010-11-18 HU HUE14151683A patent/HUE029677T2/hu unknown
- 2010-11-18 NZ NZ599439A patent/NZ599439A/en unknown
- 2010-11-18 SI SI201030688T patent/SI2361090T1/sl unknown
- 2010-11-18 CN CN201610797549.7A patent/CN106512010A/zh active Pending
- 2010-11-18 ES ES10805301.8T patent/ES2494015T3/es active Active
- 2010-11-18 ES ES14151676.5T patent/ES2559475T3/es active Active
- 2010-11-18 HR HRP20140759AT patent/HRP20140759T1/hr unknown
- 2010-11-18 ES ES14151683.1T patent/ES2595077T3/es active Active
- 2010-11-18 MX MX2012005347A patent/MX2012005347A/es active IP Right Grant
- 2010-11-18 ES ES14151678.1T patent/ES2623503T3/es active Active
- 2010-11-18 JP JP2012539433A patent/JP5890780B2/ja active Active
- 2010-11-18 CA CA2778301A patent/CA2778301C/en active Active
- 2010-11-18 RS RS20160833A patent/RS55206B1/sr unknown
- 2010-11-18 MY MYPI2012002073A patent/MY159393A/en unknown
- 2010-11-18 CN CN201610795817.1A patent/CN107050455B/zh active Active
- 2010-11-18 PL PL14151678T patent/PL2722044T3/pl unknown
- 2010-11-18 LT LTEP14151683.1T patent/LT2722045T/lt unknown
- 2010-11-18 SI SI201031291T patent/SI2722045T1/sl unknown
- 2010-11-18 EP EP10805301.8A patent/EP2361090B1/en active Active
- 2010-11-18 PE PE2012000686A patent/PE20121483A1/es active IP Right Grant
- 2010-11-18 AU AU2010320598A patent/AU2010320598B2/en active Active
- 2010-11-18 CN CN201510047631.3A patent/CN104856999A/zh active Pending
- 2010-11-18 PL PL10805301T patent/PL2361090T3/pl unknown
- 2010-11-18 DK DK10805301.8T patent/DK2361090T3/da active
- 2010-11-18 EA EA201290356A patent/EA026815B1/ru active Protection Beyond IP Right Term
- 2010-11-18 PT PT108053018T patent/PT2361090E/pt unknown
- 2010-11-18 EP EP14151678.1A patent/EP2722044B1/en active Active
- 2010-11-18 DK DK14151683.1T patent/DK2722045T3/en active
- 2010-11-18 WO PCT/IB2010/003106 patent/WO2011061622A1/en not_active Ceased
- 2010-11-18 PH PH1/2012/500887A patent/PH12012500887A1/en unknown
- 2010-11-18 CN CN201510046972.9A patent/CN104856998A/zh active Pending
- 2010-11-18 PL PL14151683T patent/PL2722045T3/pl unknown
- 2010-11-18 CN CN201610795827.5A patent/CN106421793B/zh active Active
- 2010-11-18 AP AP2012006278A patent/AP3083A/xx active
- 2010-11-18 EP EP14151676.5A patent/EP2727590B1/en active Active
- 2010-11-18 BR BR112012011485-9A patent/BR112012011485B1/pt active IP Right Grant
-
2012
- 2012-04-13 TN TNP2012000170A patent/TN2012000170A1/en unknown
- 2012-04-26 CR CR20120216A patent/CR20120216A/es unknown
- 2012-05-03 IL IL219576A patent/IL219576A/en active IP Right Grant
- 2012-05-10 NI NI201200090A patent/NI201200090A/es unknown
- 2012-05-15 DO DO2012000138A patent/DOP2012000138A/es unknown
- 2012-05-16 CL CL2012001276A patent/CL2012001276A1/es unknown
- 2012-05-17 EC ECSP12011907 patent/ECSP12011907A/es unknown
- 2012-05-18 GT GT201200156A patent/GT201200156A/es unknown
- 2012-05-18 CO CO12082329A patent/CO6551693A2/es not_active Application Discontinuation
- 2012-05-18 CU CU2012000078A patent/CU24048B1/es active IP Right Grant
- 2012-06-11 MA MA34953A patent/MA33810B1/fr unknown
-
2014
- 2014-08-18 SM SM201400112T patent/SMT201400112B/xx unknown
-
2016
- 2016-02-24 HK HK16102110.3A patent/HK1214148A1/zh unknown
- 2016-02-24 HK HK16102109.6A patent/HK1214147A1/zh unknown
- 2016-10-05 HR HRP20161277TT patent/HRP20161277T1/hr unknown
- 2016-10-05 CY CY20161100991T patent/CY1118062T1/el unknown
-
2017
- 2017-03-14 HR HRP20170419TT patent/HRP20170419T1/hr unknown
-
2022
- 2022-12-16 US US18/082,737 patent/US12042494B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2494015T3 (es) | Composiciones para tratar nauseas y vómitos de origen central | |
| ES2866933T3 (es) | Regímenes de dosificación de amisulprida para tratar náuseas y vómitos | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| JP2018505882A5 (https=) | ||
| JP2012502047A5 (https=) | ||
| CO2022008437A2 (es) | Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina | |
| JP2020500864A5 (https=) | ||
| JP2015522015A5 (https=) | ||
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| RU2019121690A (ru) | Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак | |
| JP2016515137A5 (https=) | ||
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| JP2016531853A5 (https=) | ||
| JP2019509309A5 (https=) | ||
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| JP2018505901A5 (https=) | ||
| Gelb et al. | Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year study | |
| CA2829130A1 (en) | Ezatiostat for treating multiple myeloma | |
| Chapman et al. | P234 QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study | |
| CN112437661A (zh) | 苯甲酸或其盐用于预防或治疗抗n-甲基-d-天冬氨酸受体脑炎的用途 |